Hospital
Mymichigan Medical Center Tawas
Mymichigan Medical Center Tawas was paid $9.11M by Medicaid between Jan 2018 and Dec 2024, across 181 billing codes. Its largest line is 99284, emergency room visit (serious) — 22% of everything it billed.
33Billing provider infoMYMICHIGAN MEDICAL CENTER TAWAS
TAWAS CITY, MI 48763
TAWAS CITY, MI 48763
33aNPI1194713461assigned 10/11/2005
33bProvider typeGeneral Acute Care Hospital
28Total paid$9.11M
24GClaims355,184
24DCodes billed181
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Michigan
Rank by total paid#66 of 86
Median peer was paid$21.55M
This provider vs. median0.4×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official JAMES, SARAH controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 48,836 | $1.31M | |
| 2019 | 56,179 | $1.31M | |
| 2020 | 42,112 | $1.07M | |
| 2021 | 54,153 | $1.41M | |
| 2022 | 58,101 | $1.40M | |
| 2023 | 56,765 | $1.45M | |
| 2024incomplete | 39,038 | $1.15M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 22% | 12,438 | 11,509 | $2.01M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 19% | 15,307 | 14,595 | $1.75M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 18% | 6,239 | 5,785 | $1.67M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 7.8% | 7,593 | 6,875 | $708K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 3.5% | 2,167 | 2,063 | $320K |
| 96375 | Therapeutic injection; each additional sequential IV push | 2.0% | 5,943 | 5,143 | $187K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 2.0% | 7,483 | 1,987 | $185K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.0% | 2,714 | 2,683 | $182K |
| 70450 | Computed tomography, head or brain; without contrast material | 1.7% | 1,884 | 1,799 | $156K |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.7% | 4,935 | 4,315 | $155K |
| 71045 | Radiologic examination, chest; single view | 1.6% | 4,201 | 3,944 | $147K |
| 71046 | Radiologic examination, chest; 2 views | 1.3% | 3,312 | 3,176 | $121K |
169 more codes
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.3% | 3,190 | $115K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.1% | 997 | $105K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.1% | 1,151 | $98K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | 1.0% | 1,924 | $92K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 1,627 | $68K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 158 | $61K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 1,033 | $58K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 552 | $52K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 4,593 | $50K |
| 80061 | Lipid panel | <1% | 5,405 | $48K |
| 73564 | <1% | 1,576 | $46K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 176 | $37K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 1,445 | $34K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 5,954 | $33K |
| 80053 | Comprehensive metabolic panel | <1% | 19,290 | $31K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 3,070 | $30K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 480 | $26K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 22,240 | $26K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 221 | $24K |
| 72100 | <1% | 835 | $24K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 436 | $23K |
| 86900 | <1% | 1,488 | $23K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,628 | $22K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 1,830 | $21K |
| 73030 | <1% | 1,169 | $20K | |
| 76830 | Ultrasound, transvaginal | <1% | 342 | $20K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 5,303 | $17K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,179 | $15K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 3,259 | $14K |
| 73610 | <1% | 1,083 | $14K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 1,154 | $14K |
| 73110 | <1% | 799 | $13K | |
| 76801 | <1% | 191 | $11K | |
| 94060 | <1% | 96 | $11K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 3,428 | $11K |
| 73630 | <1% | 948 | $11K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 32,476 | $11K |
| 73130 | <1% | 757 | $10K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 172 | $10K |
| 97162 | <1% | 210 | $10K | |
| 72110 | <1% | 208 | $7K | |
| 59025 | Fetal non-stress test | <1% | 82 | $7K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 4,887 | $6K |
| S4005 | Interim labor facility global (labor occurring but not resulting in delivery) | <1% | 65 | $6K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 6,315 | $6K |
| 87070 | <1% | 1,812 | $6K | |
| 84702 | <1% | 1,411 | $5K | |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 15 | $5K |
| G0378 | Hospital observation service, per hour | <1% | 30 | $5K |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 13 | $5K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 518 | $5K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 24 | $4K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 3,547 | $4K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 684 | $4K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 855 | $4K |
| 82607 | <1% | 663 | $3K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 36 | $3K |
| 84439 | <1% | 1,089 | $3K | |
| 74018 | <1% | 277 | $3K | |
| 97161 | <1% | 75 | $3K | |
| 97035 | <1% | 524 | $3K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 226 | $3K |
| 86850 | <1% | 1,575 | $3K | |
| 87186 | <1% | 1,460 | $2K | |
| 72050 | <1% | 77 | $2K | |
| 73502 | <1% | 147 | $2K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 237 | $2K |
| 85610 | <1% | 7,055 | $2K | |
| 83540 | <1% | 985 | $2K | |
| 87340 | <1% | 758 | $2K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 3,197 | $2K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 17 | $2K |
| 83550 | <1% | 537 | $2K | |
| 85027 | <1% | 1,535 | $2K | |
| 87088 | <1% | 1,058 | $2K | |
| 86140 | <1% | 1,190 | $2K | |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 27 | $1K |
| 81001 | <1% | 1,799 | $1K | |
| 86803 | <1% | 438 | $1K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 17 | $1K |
| 82728 | <1% | 250 | $1K | |
| 80076 | <1% | 1,473 | $1K | |
| 83735 | <1% | 3,526 | $1K | |
| 82570 | <1% | 557 | $976.16 | |
| 86592 | <1% | 540 | $950.43 | |
| 82043 | <1% | 460 | $910.90 | |
| 83880 | <1% | 1,148 | $891.04 | |
| 86780 | <1% | 161 | $815.83 | |
| 81003 | <1% | 8,298 | $802.07 | |
| 84153 | <1% | 78 | $678.00 | |
| 71271 | <1% | 13 | $656.04 | |
| 82550 | <1% | 3,471 | $635.87 | |
| 83690 | <1% | 4,541 | $635.24 | |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 117 | $630.44 |
| 93971 | <1% | 12 | $583.56 | |
| 87081 | <1% | 233 | $560.86 | |
| 87077 | <1% | 219 | $522.42 | |
| 85652 | <1% | 633 | $503.00 | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 22 | $499.88 |
| 85730 | <1% | 4,977 | $464.34 | |
| 82150 | <1% | 2,414 | $463.97 | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 14 | $430.37 |
| 73080 | <1% | 37 | $429.11 | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 1,448 | $411.16 |
| 82746 | <1% | 62 | $409.78 | |
| 86901 | <1% | 1,463 | $355.08 | |
| 85007 | <1% | 804 | $346.05 | |
| 87420 | <1% | 611 | $322.02 | |
| 82951 | <1% | 56 | $288.64 | |
| 86762 | <1% | 89 | $279.01 | |
| 72170 | <1% | 27 | $260.20 | |
| 74022 | <1% | 102 | $257.24 | |
| 81025 | <1% | 3,611 | $250.62 | |
| 87205 | <1% | 201 | $204.69 | |
| 73562 | <1% | 12 | $196.89 | |
| 86317 | <1% | 42 | $163.00 | |
| 93017 | <1% | 41 | $157.35 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 1,242 | $145.81 |
| 84144 | <1% | 22 | $140.97 | |
| 87800 | <1% | 12 | $139.40 | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 399 | $119.66 |
| 85379 | <1% | 446 | $114.79 | |
| 84703 | <1% | 419 | $101.17 | |
| 73140 | <1% | 27 | $92.56 | |
| 84484 | <1% | 4,080 | $90.19 | |
| 83605 | <1% | 2,332 | $80.32 | |
| 86038 | <1% | 12 | $65.73 | |
| 87040 | <1% | 898 | $53.05 | |
| 83874 | <1% | 1,264 | $52.94 | |
| 82962 | <1% | 1,056 | $42.30 | |
| 82553 | <1% | 3,032 | $40.60 | |
| 87634 | <1% | 109 | $39.17 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 3,073 | $27.00 |
| 87150 | <1% | 31 | $25.68 | |
| 88304 | <1% | 13 | $25.54 | |
| 90715 | <1% | 505 | $23.93 | |
| 82565 | <1% | 13 | $19.09 | |
| 84156 | <1% | 12 | $9.05 | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 5,939 | $5.79 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 3,431 | $4.08 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 5,709 | $0.72 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | 0% | 397 | $0.00 |
| J7120 | Ringers lactate infusion, up to 1000 cc | 0% | 1,604 | $0.00 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | 0% | 1,085 | $0.00 |
| 94729 | 0% | 53 | $0.00 | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 24 | $0.00 |
| J2270 | Injection, morphine sulfate, up to 10 mg | 0% | 807 | $0.00 |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | 0% | 12 | $0.00 |
| 29125 | 0% | 12 | $0.00 | |
| C9113 | Injection, pantoprazole sodium, per vial | 0% | 28 | $0.00 |
| 94726 | 0% | 53 | $0.00 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | 0% | 66 | $0.00 |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 13 | $0.00 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | 0% | 1,107 | $0.00 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 0% | 791 | $0.00 |
| 96376 | 0% | 761 | $0.00 | |
| J2060 | Injection, lorazepam, 2 mg | 0% | 398 | $0.00 |
| J2704 | Injection, propofol, 10 mg | 0% | 2,010 | $0.00 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | 0% | 1,266 | $0.00 |
| J0690 | Injection, cefazolin sodium, 500 mg | 0% | 50 | $0.00 |
| A9270 | Non-covered item or service | 0% | 5,998 | $0.00 |
| J1170 | Injection, hydromorphone, up to 4 mg | 0% | 1,498 | $0.00 |
| A9585 | Injection, gadobutrol, 0.1 ml | 0% | 25 | $0.00 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | 0% | 7,519 | $0.00 |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | 0% | 36 | $0.00 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | 0% | 100 | $0.00 |
| 12001 | 0% | 51 | $0.00 | |
| 88141 | 0% | 15 | $0.00 | |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | 0% | 20 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialJAMES, SARAH (MANAGER PATIENT ACCOUNTING)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.